Senseonics (NYSE:SENS) shares ticked up after hours today on third-quarter results that beat the consensus sales forecast.
Shares of SENS rose 2.1% to $6.87 apiece in post-market trading today.
The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $19.5 million. That equals 43¢ per share on sales of $8.1 million for the three months ended Sept. 30, 2025.
Senseonics recorded an 18.5% bottom-line gain on a sales increase of 90%. The company’s EPS landed 3¢ behind expectations on Wall Street. Sales topped estimates, though, as experts forecast $7.9 million in revenue.
The company attributed its growth to an approximately 160% increase in new patients in the U.S. compared to the prior year.
New patient growth comes as a result of increased investment in direct-to-consumer (DTC) marketing, the company said. It recorded the highest number of new patient starts in its history in September. This boost comes ahead of Senseonics fully assuming commercial responsibility for its Eversense 365 long-term implantable continuous glucose monitor (CGM) systems next year after agreeing to end its distribution deal with Ascensia Diabetes Care.
(Learn more about Senseonics and the CGM market in our in-depth MedTech Market Report on CGMs, available to purchase at MassDevice)
Senseonics projects full-year net revenue to total approximately $35 million as it continues to roll out Eversense 365 in the U.S. This outlook assumes approximately doubling its global patient base during 2025. This lands within the range previously projected by the company in August.
The company also executed a 1-for-20 reverse stock split. This brought the number of outstanding shares of common stock to approximately 41 million. It also plans to transfer its stock exchange listing to the Nasdaq Global Market from the NYSE, effective Nov. 17.
Commentary from Senseonics leadership and analysts
Tim Goodnow, Senseonics president and CEO, said the company continues to advance its portfolio, too. It expects CE mark for Eversense 365 by the end of the year, with a European launch planned for the first half of 2026. Additionally, Goodnow said the company continues working toward an FDA investigational device exemption (IDE) submission for its next-generation Gemini transmitter-less CGM by the end of this year.
“The third quarter of 2025 was a record-setting quarter, highlighted by all-time highs in new patient shipments, insertions and our patient base,” Goodnow said. “Our hybrid DTC and provider commercial approach continues to accelerate awareness, competitiveness, and growth in Eversense 365 with now approximately 90% of our new users switching from other CGMs. We expect resuming commercialization of Eversense will enable us to control our own destiny and continue the momentum behind Eversense, driving further revenue growth.”
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang maintain a “Neutral” rating on Senseonics. They said management notes a likely one-time inventory dynamic as the company transitions commercial operations. According to the analysts, Ascensia keeps around 60-90 days of supply as inventory. However, Senseonics targets closer to 30 days of supply, although it doesn’t expect an impact to 2025 inventory.
The analysts also note that the fourth quarter includes the one-year anniversary of the Eversense 365 launch. This means patients should be set for their first re-insertions.
“While we have been encouraged by the progress [Senseonics] has made in advancing the adoption of Eversense 365, we remain on the sidelines as we await more consistent commercial execution paired with opex leverage,” the analysts say.
